Researchers from Simon Fraser University have unveiled an artificial intelligence framework that could transform drug development and accelerate the ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.

Dr. Aaron Gerds explained when treatment with rusfertide will become accessible for patients with a myeloproliferative neoplasm like polycythemia vera.

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and ...

Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

The US Food and Drug Administration recently announced the launch of a regulatory incentive program pilot program, the ...

The NDA for the gonorrhea indication is supported by data from the EAGLE-1 study, which compared the safety and efficacy of oral gepotidacin to a standard of care combination.